ProCE Banner Series

Experts Discuss Advances in Newly Diagnosed Multiple Myeloma: The Impact of More Intensive Therapy on Clinical Outcomes

Join us live or virtually for an expert-led satellite symposium taking place in Madrid, Spain. This symposium will be held as part of the European Hematology Association 2024 Hybrid Congress and will focus on intensive therapy options for newly diagnosed multiple myeloma. Experts will discuss the latest evidence, highlight key clinical trials, address specific challenges and treatment strategies in newly diagnosed multiple myeloma, and answer audience questions. Please note: You must be registered for the EHA 2024 Congress to attend this symposium. You may register at: https://ehaweb.org/congress/eha2024-hybrid-congress/registration

Who Should Attend

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with newly diagnosed multiple myeloma.

All Events

Experts Discuss Advances in Newly Diagnosed Multiple Myeloma: The Impact of More Intensive Therapy on Clinical Outcomes

Past Events

June

13

2024

7:00 PM - 8:45 PM Central European Summer Time (CEST)

In-person

Ifema Madrid Recinto Ferial, Av. del Partenón, 5, Barajas, 28042, Madrid, Spain

7:15 PM - 8:45 PM Central European Summer Time (CEST)

Virtual

Faculty

ProCE Banner Faculty
Michele Cavo, MD

Head, “Seràgnoli” Institute of Hematology
Director, Postgraduate Residency in Hematology
Full Professor of Hematology
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

ProCE Banner Faculty
Francesca Gay, MD, PhD

Associate Professor
Department of Molecular Biotechnology and Health Science
University of Torino
SC Ematologia 1
AOU Citta della Salute e della Scienza
Torino, Italy

ProCE Banner Faculty
Paul G. Richardson, MD

Director of Clinical Research
Clinical Program Leader
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Topics

Multiple Myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to optimize CD38 antibody–based quadruplet regimens for patients with newly diagnosed multiple myeloma. 

Target Audience
This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with newly diagnosed multiple myeloma.

Learning Objectives.
Upon completion of this activity, participants should be able to:

    • Integrate CD38-targeted antibodies into treatment regimens for patients with newly diagnosed multiple myeloma to improve MRD and OS
    • Identify patients with newly diagnosed multiple myeloma who are most likely to benefit from anti-CD38 antibody–based quadruplet therapy regimens
    • Evaluate the efficacy and safety data for the available CD38-targeted agents, considering the unique features of each 
    • Improve awareness of racial and socioeconomic barriers to equitable access to high-quality myeloma care, including clinical trials

Accreditation

This educational activity is not certified for CME/CE credit.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Sanofi.